While clopidogrel is a successful antiplatelet drug for PCI patients, its ineffectiveness in certain patient subsets has recently been documented, spurring an FDA boxed warning. Testing patients platelet responsiveness or their genotype has shown success, but which tests are most effective and efficacious? Further compounding these cath lab choices, newer antiplatelet agents loom as potential game changers.